Boehringer Ingelheim Reports the Commercial Availability of Humira Biosimilar

Share this

Boehringer Ingelheim Reports the Commercial Availability of Humira Biosimilar


  • The company launch adalimumab inj., an interchangeable biosimilar to Humira (adalimumab) at a low wholesale acquisition cost for the treatment of multiple chronic inflammatory diseases & is set to be priced at an 81% discount to Humira
  • The product was also approved to treat moderately to severely active Crohn's disease in children aged ≥6yrs. as well as moderately to severely active polyarticular juvenile idiopathic arthritis in children aged 2yrs.
  • Adalimumab inj. is a citrate-free formulation and is supplied as 40mg/0.8mL, 20mg/0.4mL, and 10mg/0.2mL prefilled syringes and as a 40mg/0.8mL prefilled autoinjector. The biosimilar is also available under the brand name Cyltezo

Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim

Related News:- Boehringer Ingelheim Reports the Commercial Availability of Cyltezo, an Interchangeable Biosimilar to Humira

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions